Cantor Fitzgerald Reaffirms Overweight Rating for Anteris Technologies Global (NASDAQ:AVR)

Anteris Technologies Global (NASDAQ:AVR)‘s stock had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald in a research report issued on Friday,Benzinga reports. They presently have a $15.00 price objective on the stock. Cantor Fitzgerald’s target price points to a potential upside of 189.02% from the company’s previous close.

Several other analysts also recently weighed in on AVR. Weiss Ratings restated a “sell (e+)” rating on shares of Anteris Technologies Global in a report on Monday, December 29th. Wells Fargo & Company initiated coverage on shares of Anteris Technologies Global in a report on Wednesday, March 11th. They set an “overweight” rating and a $16.00 target price on the stock. Finally, Lake Street Capital reissued a “buy” rating and set a $15.00 target price on shares of Anteris Technologies Global in a research report on Friday, January 23rd. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Anteris Technologies Global currently has an average rating of “Moderate Buy” and a consensus price target of $15.33.

Anteris Technologies Global Stock Down 3.7%

Shares of NASDAQ:AVR opened at $5.19 on Friday. The business’s 50 day moving average is $5.96 and its 200 day moving average is $5.13. The stock has a market cap of $504.63 million, a P/E ratio of -2.03 and a beta of 1.15. Anteris Technologies Global has a 52-week low of $2.34 and a 52-week high of $6.95. The company has a quick ratio of 0.73, a current ratio of 0.73 and a debt-to-equity ratio of 0.01.

Anteris Technologies Global (NASDAQ:AVR) last issued its earnings results on Thursday, February 26th. The company reported ($0.75) earnings per share for the quarter. Anteris Technologies Global had a negative net margin of 4,921.27% and a negative return on equity of 536.04%. The firm had revenue of $0.31 million for the quarter. Sell-side analysts predict that Anteris Technologies Global will post -2.66 EPS for the current year.

Insider Buying and Selling

In other news, major shareholder L1 Capital Pty Ltd bought 5,000,000 shares of Anteris Technologies Global stock in a transaction on Thursday, January 22nd. The stock was acquired at an average cost of $5.75 per share, for a total transaction of $28,750,000.00. Following the completion of the acquisition, the insider owned 13,219,814 shares of the company’s stock, valued at $76,013,930.50. This trade represents a 60.83% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 4.50% of the company’s stock.

Institutional Trading of Anteris Technologies Global

Institutional investors have recently modified their holdings of the company. Marex Group plc bought a new position in shares of Anteris Technologies Global during the 2nd quarter worth approximately $641,000. Price T Rowe Associates Inc. MD boosted its stake in Anteris Technologies Global by 78.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 22,875 shares of the company’s stock valued at $115,000 after acquiring an additional 10,073 shares in the last quarter. Intech Investment Management LLC acquired a new stake in Anteris Technologies Global in the fourth quarter valued at approximately $67,000. Bank of America Corp DE grew its holdings in Anteris Technologies Global by 35.7% in the third quarter. Bank of America Corp DE now owns 10,631 shares of the company’s stock worth $48,000 after purchasing an additional 2,798 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Anteris Technologies Global by 35.2% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 11,744 shares of the company’s stock worth $45,000 after purchasing an additional 3,055 shares in the last quarter.

Anteris Technologies Global Company Profile

Anteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.